

## PRESS RELEASE

# Hansa Biopharma to host Q1 2025 interim results conference call

Lund, Sweden, 3 April, 2025. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January - March 2025 on 24 April, 2025. Interested parties may join the Company’s quarterly conference call on the same date at 14:00 CEST/8:00 AM ET. The event will be hosted by Søren Tulstrup, President and CEO, Evan Ballantyne, CFO, and Hitto Kaufmann, CR&DO. The call will include a review of the interim results and a business and pipeline update. It will be held in English.

Slides used in the presentation will be made available on the company website at the following link: [Financial reports](#).

To participate in the telephone conference, please use the dial-in details provided below:

Participant Dial In (Toll Free): 1-833-821-3542

Participant International Dial In: 1-412-652-1248

The webcast will be available on: <https://event.choruscall.com/mediaframe/webcast.html?webcastid=gvTS9luw>

--- ENDS ---

### Contacts for more information:

Evan Ballantyne, Chief Financial Officer  
[IR@hansabiopharma.com](mailto:IR@hansabiopharma.com)

Stephanie Kenney, VP Global Corporate Affairs  
[media@hansabiopharma.com](mailto:media@hansabiopharma.com)

### Notes to editors

#### About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company’s portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a second-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at [www.hansabiopharma.com](http://www.hansabiopharma.com) and follow us on [LinkedIn](#).

©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.